Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-exploratory Phase II Clinical Trial to Evaluating the Efficacy and Safety of Felbinac Trometamol Injection in the Treatment of Moderate to Severe Pain After Surgery

NCT03872830 is registered in ClinicalTrials.gov with Shijiazhuang Yiling Pharmaceutical Co. Ltd as lead sponsor.

NCT NCT03872830
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03872830 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-exploratory Phase II Clinical Trial to Evaluating the Efficacy and Safety of Felbinac Trometamol Injection in the Treatment of Moderate to Severe Pain After Surgery
Lead sponsor
Shijiazhuang Yiling Pharmaceutical Co. Ltd
Phase
Phase 2
Overall status
Completed
Start date
March 27, 2019
Completion date
December 5, 2019
Enrollment
165 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

pain